TD Asset Management Inc Has $9.14 Million Stock Position in Repligen Corporation $RGEN

TD Asset Management Inc raised its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 109.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,756 shares of the biotechnology company’s stock after acquiring an additional 29,128 shares during the quarter. TD Asset Management Inc’s holdings in Repligen were worth $9,136,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Bayforest Capital Ltd bought a new stake in shares of Repligen in the fourth quarter worth $32,000. Rachor Investment Advisory Services LLC bought a new position in Repligen in the fourth quarter valued at $33,000. Measured Wealth Private Client Group LLC bought a new position in Repligen in the third quarter valued at $29,000. Farther Finance Advisors LLC increased its stake in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares during the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in Repligen in the 3rd quarter valued at $65,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Up 3.8%

Repligen stock opened at $130.13 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The company’s 50-day moving average is $119.28 and its 200-day moving average is $138.32. The firm has a market capitalization of $7.34 billion, a PE ratio of 144.59, a P/E/G ratio of 2.42 and a beta of 1.09. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same period last year, the business posted $0.39 EPS. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Sell-side analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. JPMorgan Chase & Co. dropped their target price on Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Roth Mkm started coverage on Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price target for the company. Finally, Wells Fargo & Company lowered their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.